Why BGPT?
logo

Assess an author's data and outputs

See the raw experimental evidence behind an author's publications and reproducibility signals.







Press Enter ↵ to solve



    Fuel Your Discoveries




     Quick Explanation


    Jenny Stroh — science-focused strength check
    • Research focus: ferroptosis, programmed cell death signaling, and cancer biology (notably SCLC and KRAS/DLBCL contexts) with mechanistic cell-biology endpoints.
    • Publication footprint: OpenAlex shows ~645 cited-by (varies by index/time), works_count ~14, and h-index ~7.
    • Scientific signal: multiple Nature-family and Cell Death–route papers on ferroptosis mechanisms (e.g., ESCRT-III-linked kinetics; Drp1 mitochondrial fragmentation; ferroptotic secretomes).
    Note: this review is limited to the author metrics + the paper list you provided (no full bibliography scan).



     Long Explanation


    Author Review — Jenny Stroh
    Science strength assessment grounded in the bibliometrics + paper list you provided (and OpenAlex record).
    Citations by year (OpenAlex “counts_by_year” snapshot)
    Uses the provided per-year works_count and cited_by_count entries from the OpenAlex author match.
    Top cited works in the provided OpenAlex list (with DOIs)
    The ranking and citation counts come from the top_works objects included in your OpenAlex data dump.
    Selected publications provided (what they cover)
    You provided 11 paper entries (5 are from the explicit “papers:” list). Below I also include the “top_works” entries present in the OpenAlex dump when DOIs are available there.
    Paper Year Phenotype / mechanism focus Type Key evidence strength (from title/abstract only)
    Ferroptotic pores induce Ca2+ fluxes and ESCRT-III activation to modulate cell death kinetics 2020 Ferroptosis pore-linked Ca2+ flux and ESCRT-III activation; kinetic control during regulated necrosis Article Mechanistic cell-biology claim; strong internal mechanistic plausibility but requires full-method validation
    Ferroptosis response segregates small cell lung cancer (SCLC) neuroendocrine subtypes 2021 Regulated cell-death pathway availability in treatment-naïve SCLC; links ferroptosis to neuroendocrine subtypes Article Systemic analysis framing; evidence depends on dataset scale, validation, and causal tests
    Elevated FSP1 protects KRAS-mutated cells from ferroptosis during tumor initiation 2022 FSP1-mediated protection in KRAS-mutated contexts during initiation; ferroptosis resistance Article Mechanism + oncogene context; causal strength depends on controls and genetic/chemical perturbation design
    Ferroptosis triggers mitochondrial fragmentation via Drp1 activation 2025 Drp1-linked mitochondrial fission/fragmentation as a downstream ferroptosis event Article Pathway dissection implied; must check specificity (Drp1 inhibitors vs genetic perturbations)
    Dynasore Blocks Ferroptosis through Combined Modulation of Iron Uptake and Inhibition of Mitochondrial Respiration 2020 Pharmacologic specificity question: how dynasore affects iron uptake + mitochondrial respiration; ferroptosis outcome Article Potential specificity caveat: inhibitors often have pleiotropic effects
    An atlas of ferroptosis-induced secretomes 2025 Ferroptosis→secretome atlas; immune-relevant secreted proteins/non-protein components Article Atlas-style evidence; strong if validated across conditions/cell types and with robust proteomics standards
    Scientific merit (mechanistic coherence + evidence expectations)
    1) Coherent mechanistic theme: ferroptosis as a multi-node pathway
    • Stroh’s provided portfolio repeatedly targets ferroptosis at different mechanistic layers: pore/ESCRT-linked membrane disruption and Ca2+ flux kinetics
    • Downstream organelle dynamics are treated explicitly via Drp1-mediated mitochondrial fragmentation
    • Extrinsic communication with immunity is addressed with secretome atlas framing (what ferroptosis releases)
    Confidence note: I’m assessing coherence based on titles/abstract-level summaries from your dataset. I do not have the full methods/figures here, so rigor claims cannot be fully verified.
    2) Cancer translational linkage: SCLC subtype availability + KRAS initiation resistance
    • The SCLC paper frames ferroptosis as a pathway that remains available across specific treatment-naïve neuroendocrine subtypes under TP53/RB1 loss constraints
    • The KRAS/FSP1 work ties oncogenic KRAS context to ferroptosis resistance mediated by FSP1 during tumor initiation
    Skeptical lens: cancer papers often combine omics + perturbations. The causal strength depends on how many independent validations exist (cell lines, genetic models, rescue experiments, and whether multiple ferroptosis markers cohere rather than one readout driving the conclusion).
    3) Methodological red-flag category: pharmacologic inhibitors and pleiotropy
    • The dynasore work title explicitly suggests dynasore blocks ferroptosis via combined effects on iron uptake and mitochondrial respiration, which raises the well-known risk that multi-target pharmacology can confound mechanism interpretation
    What would strengthen interpretation (not provided here): concordant genetic perturbations, orthogonal ferroptosis readouts (lipid peroxidation markers, GPX4/FSP1 pathway consistency), and rescue experiments.
    4) Evidence coverage vs missing data (important limitation)
    • Your prompt includes bibliometrics and a subset of papers, not the entire publication list. Therefore, I can’t assess overall reproducibility behavior, breadth across subfields, or whether negative/failed replications exist in the full oeuvre.
    • I also cannot verify experimental design details (blinding, randomization, sample sizes, batch effects, statistical correction, pre-registration, or independent replication) without full-text methods/figures.
    Citation & productivity metrics (as provided)
    OpenAlex h-index
    7
    From OpenAlex author match.
    Cited-by count
    645
    From OpenAlex author match (snapshot/aggregation dependent).
    Works count
    14 (OpenAlex match)
    OpenAlex works_count value in the match you provided.
    Important skepticism: bibliometrics depend on indexing coverage, name disambiguation, and inclusion/exclusion of preprints. High citations don’t guarantee rigor; low citations don’t prove low quality.
    Go deeper on BGPT
    Run targeted analyses over the same author’s publications inside BGPT (raw-paper grounded).


    Feedback:    

    Updated: March 31, 2026

     BGPT Author Review


    Scientific Quality

    70%

    Based on the provided publication set and OpenAlex bibliometrics (h-index ~7; cited-by ~645), the author appears to be a productive contributor with a coherent mechanistic focus on ferroptosis and cancer-linked programmed cell death. Strengths: repeated mechanistic node targeting (pore/ESCRT-III kinetics, Drp1 mitochondrial dynamics, FSP1-mediated ferroptosis protection, and secretome outputs) suggests technical depth and theme continuity. Critical gaps: this assessment is limited to titles/abstract-level summaries and a partial publication list; I cannot verify rigor details (sample sizes, blinding, replication, statistics, batch effects) or independence of findings. A notable methodological skepticism area is pharmacologic interpretation (e.g., dynasore’s pleiotropic effects implied by the title), which can confound mechanistic claims without strong orthogonal genetic/rescue evidence.


    Communication Quality

    80%

    The author’s work titles indicate clear mechanistic framing and specificity (e.g., “Ca2+ fluxes and ESCRT-III activation,” “Drp1 activation,” “atlas of ferroptosis-induced secretomes”). However, communication quality (clarity of narrative, figure quality, accessibility) cannot be fully judged from the provided metadata alone; full-text review would be needed.


    Author Novelty

    70%

    The theme appears to be both incremental-to-mechanistic and expansionary across ferroptosis downstream events (membrane pore kinetics, mitochondrial fragmentation, secretome mapping) and cancer context. Novelty is plausibly moderate-to-high for niche mechanistic junctions, but I cannot benchmark novelty against the full field’s prior work without reading the papers and citation context.


    Scientific Rigor

    60%

    From provided information, rigor cannot be fully validated. The scientific topics suggest mechanistic experimentation and multi-layer phenotyping, which often correlates with stronger design, but the limited evidence here prevents assessment of critical rigor elements (blinding/randomization, statistical power, orthogonal validation, reproducibility across cell lines/conditions). Pharmacologic studies imply a risk of pleiotropy confounding mechanism unless countered by genetic/rescue controls.

     Hypothesis Graveyard


    “FSP1 completely blocks ferroptosis universally across KRAS mutants.” Likely false as ferroptosis sensitivity typically depends on multiple parallel lipid-peroxidation and antioxidant routes; without broad testing across models, universal claims are fragile.


    “Dynasore’s ferroptosis blockade is primarily caused by iron uptake modulation only.” Because dynasore also inhibits mitochondrial respiration per the paper framing, single-causal interpretations are unlikely without orthogonal separation-of-mechanisms evidence.

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion








    Get Ahead With Science Insights

    Custom summaries of the latest cutting edge Science research. Every Friday. No Ads.


    My BGPT






     Trending